ABT-267
|
|
|
- CAS-Nr.
- 1258226-87-7
- Englisch Name:
- ABT-267
- Synonyma:
- Ontave;ABT-267;ombitasvir;Mr. He wei;Viekira Pak);ABT-267/Ombitasvir;Ombitasvir(ABT-267);Ombitasvir, Paritaprevir, and Ritonavir;2,2'-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide;L-Prolinamide, 2,2'-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- CBNumber:
- CB02716109
- Summenformel:
- C50H67N7O8
- Molgewicht:
- 894.11
- MOL-Datei:
- 1258226-87-7.mol
|
ABT-267 Eigenschaften
- Schmelzpunkt:
- >177°C (dec.)
- Siedepunkt:
- 1065.6±65.0 °C(Predicted)
- Dichte
- 1.223±0.06 g/cm3(Predicted)
- storage temp.
- -20°C Freezer, Under inert atmosphere
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- pka
- 10.92±0.46(Predicted)
- Aggregatzustand
- Solid
- Farbe
- Off-White to Pale Beige
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
| P332+P313 |
Bei Hautreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
|
ABT-267 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Ombitasvir hydrate is a NS5A non-nucleoside polymerase inhibitor
which is approved as part of a four drug combination for the
treatment of adults with genotype 1 hepatitis C virus infection
including those with compensated cirrhosis. The four drug
combination treatment consists of ombitasvir, paritaprevir
(XXVII), ritonavir, and dasabuvir (X). This combination treatment
is marketed as Viekira Pak and was developed by Abbvie as an
all oral treatment that eliminates the need for pegylated interferon-
a injections.
Verwenden
Ombitasvir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
Definition
ChEBI: A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.
Enzyminhibitor
This N-phenylpyrrolidine-based, pan-genotypic HCV NS5A protease inhibitor (FW = 893.14 g/mol), also named ABT-267, targets Nonstructural protein 5A (NS5A), a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication.Ombitasvir exhibits low-picomolar EC50 values against Hepatitis C virus, with superior pharmacokinetics. Although ombitasvir shows a low barrier to resistance, when given as monotherapy, co-administration with other antivirals enhances its barrier to resistance. Indeed, a 12-week, Phase- 3 study demonstrated that a multi-targeted regimen consisting of ombitasvir, dasabuvir and ribavirin is highly effective and showed a low rate of treatment discontinuation.
ABT-267 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
ABT-267 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 107)Lieferanten
- ABT-267
- ombitasvir
- Ombitasvir(ABT-267)
- 2,2'-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide
- ABT-267/Ombitasvir
- L-Prolinamide, 2,2'-[[(2S,5S)-1-[4-(1,1-dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-
- Viekira Pak)
- OmbitasvirQ: What is
Ombitasvir Q: What is the CAS Number of
Ombitasvir Q: What is the storage condition of
Ombitasvir Q: What are the applications of
Ombitasvir
- Mr. He wei
- Methyl ((S)-1-((S)-2-((4-((2S,5S)-1-(4-(tert-butyl)phenyl)-5-(4-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidine-2-carboxamido)phenyl)pyrrolidin-2-yl)phenyl)carbamoyl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
- Ontave
- Ombitasvir, Paritaprevir, and Ritonavir
- 1258226-87-7
- C50H67N7O8
